Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

By Jerusalem Guy   Fasolo Angelica   Dieras Veronique   Cardoso Fatima   Bergh Jonas   Vittori Luc   Zhang Yufen   Massacesi Cristian   Sahmoud Tarek   Gianni Luca  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 447-455

Springer Publishing Company

Access to resources Recommend Favorite

Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer

By Hosoda Mitsuchika   Yamamoto Mitsugu   Nakano Kiichiroh   Hatanaka Kanako   Takakuwa Emi   Hatanaka Yutaka   Matsuno Yoshihiro   Yamashita Hiroko  

Breast Cancer Research and Treatment, Vol. 144, Iss. 2, 2014-04 ,pp. : 249-261

Springer Publishing Company

Access to resources Recommend Favorite

The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer

By Beaver Julia A   Park Ben H  

Future Oncology, Vol. 8, Iss. 6, 2012-06 ,pp. : 651-657

Future Medicine

Access to resources Recommend Favorite

The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts

By Behrens Diana   Lykkesfeldt Anne   Fichtner Iduna  

Targeted Oncology, Vol. 2, Iss. 3, 2007-07 ,pp. : 135-144

Springer Publishing Company

Access to resources Recommend Favorite

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo

By Zhu Yuanxi  

Tumor Biology, Vol. 33, Iss. 5, 2012-10 ,pp. : 1349-1362

Springer Publishing Company

Access to resources Recommend Favorite